Physician profile
Melissa Devito
NPI 1598442808
$1,196.47
in general payments reported to CMS, 2019-2025
12 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $559 · 2024: $191 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $477.53 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Heartflow, INC. | $180.28 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $150.37 | 2025 | Lifevest |
| Abbvie INC. | $138.61 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $76.33 | 2025 | Verquvo, Capvaxive |
| Exact Sciences Corporation | $43.65 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $39.23 | 2024-2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.21 | 2023 | Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $20.70 | 2025 | |
| Daiichi Sankyo INC. | $20.41 | 2023 | Injectafer |
| Shield Therapeutics INC | $13.96 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $13.19 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Devito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.